Epigral543332Specialty chemicals
Analyst recommended staying invested in Epigral with a target of 1050-1080, citing strong revenue growth plans
By ScoutQuest · · 1 min read
- Year-to-date decline
- 30 to 40 percent
- Viewer holding price
- 998 rupees
- Revenue target
- 5,000 crore rupees
- Current price
- 982 rupees
- Price target
- 1050 to 1080 rupees
Heard on business television between 14:10:06 - 14:13:06 IST.
- Viewer bought the stock, referred to as Epic/Epigral, at 998 and sought a two-year view; stock is down 30-40% this year.
- Astha Jain said the view is positive as management targets around 5,000 crore revenue in FY23 (or stated target year).
- New capacity additions were cited as a growth driver in this specialty chemicals business.
- She recommended staying invested with an upside target of 1050 to 1080.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Epigral
Epigral schedules Elara Securities investor/analyst plant visit at Dahej on 22 October 2026
21 Oct 2026
Epigral to hold one-on-one video meeting with Elara Securities (India) Pvt Ltd on 14 October 2026
13 Oct 2026
Source: Live TV News Channel · 13 Oct 2026
The call above is Astha Jain, Hem Securities's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.